Saint Barnabas Doctor: Hepatitis Tells About COVID-19

Livingston, NJ — “There are many lessons to be learned from viral hepatitis to overcome COVID-19.” These words from Suwan, a doctor at St. Bernabath Medical Center in Livingston, come Tuesday. It was part of a phrase that called for action on World Hepatitis Day.

Wang knows the complexities and challenges of living with hepatitis. After all, she has lived with hepatitis B on her own for years.

“For a long time, I was not afraid to blame my diagnosis during medical training or in my personal life,” Wang said. “When I worked in New York City servicing Asians and defended locally and nationally for more resources, it was finding patients who shared their personal experience. Was always a challenge.”

“Most of my patients were as painful as immigrants, and were willing to endanger their lives and families by coming out,” continued the King. “I have recognized a vicious circle: illnesses affecting marginalized communities continue to be overlooked without a call for action.”

Ultimately, the King realized that her anger needed to outweigh her fears and discomfort. Eventually, she began to identify herself as a person with hepatitis B.

“I’m listening to patients and other people around the world who have hepatitis, so I look at the other side of medical progress-lifesaving innovation is often a hand to those who need it most. I don’t receive it.” “Therefore, lives that are easily saved are lost…and that’s where urgent things should be.”

These life-saving innovations also apply to coronavirus pandemics, Wang wrote in an editorial.

“We have seen that effective intervention is not enough. We need accessibility and streamlined delivery to affected communities,” Wang said. “We need to break down the complexity and cost barriers that are currently occurring in healthcare systems, reorganize service delivery and make it people-d. We can’t continue. Without it, tremendous innovation reaches only a small part of the population, a large band of people who are most afflicted with disease.”

Read her full opeded below.

“World Hepatitis Day is celebrated on July 28th and is one of the only seven disease-specific days celebrated by the World Health Organization (WHO), which was set by WHO for viral hepatitis 2030. It’s a milestone year with 10 years left to reach the goal.

“The hepatitis B and C viruses kill 1.43 million people each year, mainly due to cirrhosis and liver cancer, which has more than doubled the death toll from the COVID-19 pandemic so far. Hepatitis is not under global urgency and is often overlooked.

“COVID-19 is a new disease and is an important tool needed to fight infectious diseases: diagnosis (must be of high quality and readily available), preventive strategy (must know the route of infection), disease Natural course (requires rigorous research that can be time consuming) and vaccines (if effective and safe, they can dramatically stop the spread of infection and protect the population).

“These interventions exist for hepatitis-we can both remove hepatitis B (including the rapid point-of-care test), hepatitis B (can suppress the virus) and hepatitis C (removing the virus). Have a very accurate screening test of oral treatment for both (both available) and vaccines hepatitis B (which dramatically reduces the acute infection rate). The infection route is blood-borne (COVID-19 Preventive measures include blood product screening, safe injection, harm mitigation, and prevention. These equipment of highly effective interventions eradicate global hepatitis. Is within reach, and can take over # Hepatitis Free Future to the next generation.

“I am a doctor and live in a world that applies these interventions. I have a screening program in the community and in our hospitals that provides linkage-to-care for people with hepatitis. I developed a program and a treatment program, which was improved by being monitored and receiving medication. It was my most rewarding that the patient witnessed a cure for hepatitis C after a course of only 8 weeks of oral medication. It’s one of my professional experiences.

“I also live with hepatitis B myself. For a long time I wasn’t open about my diagnosis because I could be accused during medical training and in my personal life. Working in New York When serving and advocating locally in Asia and for more resources nationwide, it was always a challenge to find patients who shared their personal experiences. Most of my patients Was as hard as immigrants and was not going to endanger their lives and families by coming out. I recognized a vicious cycle-a disease affecting a marginalized community calls for action. Without being voiced, I continue to be overlooked.I finally realized my anger that needed to overcome my fears and discomforts, and gradually began to recognize myself as a person with hepatitis B infection. Patients and other people around the world suffering from illness, I see the other side of medical progress — lifesaving innovation is number one, so now lives that can be easily saved are lost. Masu-and that’s where there must be urgency.

“Maybe the cost, but the prices for screening tests, vaccines, and oral drugs have all fallen. This includes common direct-acting antiviral drugs for hepatitis C. Type B A quick test for hepatitis is available for $1 USD, but because there are no opportunities for profit, no manufacturer invests in the FDA registration process for low-cost testing, so the cost of healthcare systems in the US is high. It’s easy to maintain the status quo of continuous, laboratory-based serology testing, even at high prices.The high cost of prescription drugs in the US has already been explained. Surprisingly, tenofovir disoproxil fumarate. When (TDF) became generic in 2018, hepatitis B patients were actually paying up to $125 (because the generic maker was given market exclusivity) while The median annual supply is $32.

“With COVID-19, we’re desperately waiting for vaccines to change the direction of the pandemic. In the case of hepatitis B, such vaccines prove to be safe and lead to long-term immunity.” Hepatitis B has been traced to eradicated disease pathways such as smallpox and polio, but while pediatric vaccination has a very high prevalence (85%), As the WHO has recommended for many years, the first birth rate of all babies is a very low range of 43%, which prevents mother-to-child transmission and, as a result, 1.8 million people, even in the era of vaccines. It is estimated that a 5-year-old child in Japan is infected with hepatitis B.

“Unfortunately, the vaccination rate for adults is even lower, and I hope this is not the fate of the COVID-19 vaccine. Despite the hepatitis B vaccine being the world’s first cancer-preventing vaccine, the US adult population Only 25% of this vaccination gap is disastrous and the CDC estimates about 22,000 new hepatitis B infections each year.Recent innovations are 2 doses over 1 month instead of 3 doses over 6 months. Hepatitis B vaccine is a drop-off for vaccinated patients Wider adoption of this vaccine may help boost low adult immunity, yet our system is not necessarily an innovation It’s not designed to fill the gap: Reimbursement of the service model, the more visits you make, the more revenue your healthcare system will get, and the simpler regimen won’t pay off.

“There are many lessons to be learned from viral hepatitis to overcome COVID-19. We have found that effective intervention is not enough. Accessibility to affected communities and Streamlined delivery is needed Barriers need to be dismantled The complexity and cost issues that are currently occurring in our healthcare system, reorganization of service delivery to bring people to the center The current situation cannot be continued, mostly due to illness.”

Send local news tips and fix requests to [email protected]

Don’t forget to visit the Patch Livingston Facebook page. For more information Posting announcements and events Go to your local patch site. Sign up for the patch email newsletter..